Session Abstract – PMWC 2020 Silicon Valley

An increasing number of researchers and executives with successful careers in academia and at life-science companies are moving into venture capital. The panel will explore the challenges of making the transition and relay first-hand experience testimonials from individuals who have successfully made the transition. The panelists will provide insights for researchers and industry executives that are considering a career change and will also relay thoughts on their personal transitions into venture and how these diverse backgrounds influence investment decisions.

 Session Chair Profile

M.D., M.B.A, Managing Partner, Section 32; Former Chairman, Foundation Medicine

Dr. Pellini is Managing Partner of Section 32, a venture fund that invests in companies and inventors that are changing the way humans use technology and the way technology betters humanity. Previously, he served as the chairman of Foundation Medicine (NASDAQ:FMI) and before that as the CEO (May 2011-February 2017). He currently serves as a member of the Board of Directors for Tango Therapeutics, Singular Genomics, Adaptive Biotechnologies, the Personalized Medicine Coalition, Thrive, and the Mission Hospital Foundation, in addition to his Board Chair position with Foundation Medicine. As a physician with more than 20 years of executive experience with companies at the forefront of clinical diagnostics and genomics, Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. Dr. Pellini is a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Cancer Institute (Provident/St. Joseph Health). Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.

 Speaker Profile

Ph.D., General Partner, Andreessen Horowitz

Vijay Pande is a general partner at Andreessen Horowitz where he leads the firm’s investments in companies at the cross section of biology and computer science including areas such as the application of computation, machine learning, and artificial intelligence into biology and healthcare as well as the application of novel transformative scientific advances. Previously, Vijay was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University. He led a team of researchers pioneering computational methods and their application to medicine and biology, resulting in over 200 publications, two patents, and two novel drug treatments. Concurrently, he was the director of the Biophysics program at Stanford, where he led a team of over 50 Stanford faculty members and propelled the program to the top in the country. Vijay received a BA in Physics from Princeton University and a PhD in Physics from MIT.